NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









PAQ Therapeutics

PAQ Therapeutics

Private
Burlington, MassachusettsHealthcare & Life Scienceshttps://www.paqtx.com/

Last Round

Series B

Extension

Jan 22, 2026

Total Funding Raised

$153M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

PAQ Therapeutics is a biotechnology company developing best- and first-in-class KRAS degraders for lethal cancers lacking effective treatment options.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

autophagy-dependent degradationtargeted protein degradationpac-man drugsneurodegenerative diseasedrug discoveryprotein degraderundruggable proteinsbiotechsmall-molecule degradersai-augmented drug discoverytherapeutic developmenttargeted therapytpddrug pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

PAQ Therapeutics Comps

Public and private peers based on sector, stage, and business model.

PAQ Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

PAQ Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionJan 22, 2026
Series BMay 7, 2025
Series AJul 15, 2021
SeedNov 8, 2020
SeedJun 1, 2020

PAQ Therapeutics Investors

Notable investors and investment history

PAQ Therapeutics investors
InvestorRounds
MatrixSeed, Series A
BioTrack CapitalSeries B Extension, Series B
Nest Bio VenturesSeed, Series A
MSA CapitalSeries A
Bayland CapitalSeries B Extension
MPCSeed, Series A
Huagai CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 16, 2026

    Monthly visitors grew 398% MoM, from 386 to 1.9K.

  • Jan 22, 2026

    $38M round with participation from Merck and J&J.

PAQ Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

PAQ Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about PAQ Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersBurlington, Massachusetts
Employee Range11
Year Founded2020
Last FundingJan 22, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.